Effect of the Quadruple Therapy of Eradicating Helicobacter Pylori on Gastrointestinal Microecology
-
摘要: 幽门螺杆菌(Helicobacter plyori, Hp)的感染及治疗是全球普遍关注的热点问题。近年来全球多数地区Hp耐药性增加且根除率下降。目前根除Hp的一线疗法为四联疗法, 使用的抗生素比三联疗法剂量更大、疗程更长, 这会造成胃肠道菌群失调, 胃肠道微生态系统的组成发生改变, 优势菌群减少, 甚至导致小肠细菌过度生长、艰难梭菌的定植等。上述改变很可能与在根除Hp过程中产生的不良反应及根除后感染复发有关。Abstract: The infection and treatment of Helicobacter pylori(Hp) is a hot topic of global concern. However, in recent years, Hp resistance has increased and the eradication rate has decreased in most regions of the world. Therefore, current first-line therapy to eradicate Hp has been adjusted to the quadruple therapy, using more antibiotics and longer duration than the triple therapy. It has an inevitable effect on the gastrointestinal microecology and causes an imbalance of gastrointestinal flora, changes of the composition of the gastrointestinal micro-ecological system, decrease of dominant flora, overgrowth of the intestinal bacteria, and colonization of Clostridium difficile, etc. The above changes are likely related to the adverse reactions during the eradication of Hp and the recurrence of infection thereafter.
-
Key words:
- Helicobacter pylori /
- quadruple therapy /
- gastrointestinal microecology
利益冲突 无 -
[1] Martin ME, Solnick JV. The gastric microbial community, Helicobacter pylori colonization, and disease[J]. Gut Microbes, 2014, 5:345-350. doi: 10.4161/gmic.28573 [2] 刘文忠. 《幽门螺杆菌感染的处理:Maastricht Ⅴ/Florence共识报告》解读[J].胃肠病学, 2016, 21:577-584. doi: 10.3969/j.issn.1008-7125.2016.10.001 [3] Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease[J]. Gut, 2015, 64:1650-1668. doi: 10.1136/gutjnl-2014-307595 [4] 高杰, 林倩云, 彭文玲, 等.幽门螺杆菌和胃微生态系统与胃疾病的关系[J].中华消化杂志, 2017, 37:205-208. doi: 10.3760/cma.j.issn.0254-1432.2017.03.018 [5] 何桂珍.肠道屏障功能与细菌移位[J].协和医学杂志, 2012, 3:260-264. doi: 10.3969/j.issn.1674-9081.2012.03.003 [6] Zhernakova A, Kurilshikov A, Bonder MJ, et al. Popula-tion-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J]. Science, 2016, 352:565-569. doi: 10.1126/science.aad3369 [7] 潘飞, 任荣荣, 杨云生, 等.肠道微生态与结直肠癌关系的研究进展[J].循证医学, 2017, 17:120-124. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xzyx201702013 [8] 于阿莉, 刘响, 安莹莹, 等.肠道菌群失调与慢性便秘的研究进展[J].国际消化病杂志, 2017, 37:83-86. doi: 10.3969/j.issn.1673-534X.2017.02.005 [9] Hartstra AV, Bouter KE, Bäckhed F, et al. Insights into the role of the microbiome in obesity and type 2 diabetes[J]. Diabetes Care, 2015, 38:159, 165. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM25538312 [10] Yin YN, Wang CL, Liu XW, et al. Gastric and duodenum microflora analysis after long-term Helicobacter pylori infection in Mongolian Gerbils[J].Helicobacter, 2011, 16:389-397. doi: 10.1111/j.1523-5378.2011.00862.x [11] Mi JK, Kim H. Anticancer Effect of Lycopene in Gastric Carcinogenesis[J]. J Cancer Prev, 2015, 20:92-96. doi: 10.15430/JCP.2015.20.2.92 [12] Avilesjimenez F, Vazquezjimenez F, Medranoguzman R, et al. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer[J]. Sci Rep, 2014, 4:4202. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935187/ [13] Wang L, Zhou J, Xin Y, et al. Bacterial overgrowth and diversification of microbiota in gastric cancer[J]. Eur J Gastroenterol Hepatol, 2016, 28:261-266. doi: 10.1097/MEG.0000000000000542 [14] Dore MP, Cipolli A, Ruggiu MW, et al. Helicobacter pylori eradication may influence timing of endoscopic surveillance for gastric cancer in patients with gastric precancerous lesions:A retrospective study[J]. Medicine, 2018, 7:e9734. http://europepmc.org/article/PMC/5794400 [15] Khosravi Y, Seow SW, Amoyo AA, et al. Helicobacter pylori infection can affect energy modulating hormones and body weight in germ free mice[J]. Scientific Reports, 2015:8731. https://pubmed.ncbi.nlm.nih.gov/25736205/ [16] Lebwohl B, Spechler SJ, Wang TC, et al. Use of proton pump inhibitors and subsequent risk of celiac disease[J].Dig Liver Dis, 2014, 46:36-40. doi: 10.1016/j.dld.2013.08.128 [17] Castaño-Rodríguez N, Kaakoush NO, Lee WS, et al. Dual role of Helicobacter and Campylobacter species in IBD:a systematic review and meta-analysis[J]. Gut, 2017, 66:235-249. doi: 10.1136/gutjnl-2015-310545 [18] Zhang YX, Zhou LY, Song ZQ, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing:a prospective serial study[J]. World J Gastroenterol, 2015, 21:2786-2792. doi: 10.3748/wjg.v21.i9.2786 [19] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌科研协作组成虹, 胡伏莲, 谢勇, 等.中国幽门螺杆菌耐药状况以及耐药对治疗的影响——全国多中心临床研究[J].胃肠病学, 2007, 12:525-530. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=wcbx200709005 [20] Jakobsson HE, Jernberg C, Ersson AF, et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome[J]. PLoS One, 2010, 5:e9836. doi: 10.1371/journal.pone.0009836 [21] Iizumi T, Battaglia T, Ruiz V, et al. Gut Microbiome and Antibiotics[J]. Arch Med Res, 2017, 48:727-734. doi: 10.1016/j.arcmed.2017.11.004 [22] Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype[J]. World J Gastroenterol, 2014, 20:6400-6411. doi: 10.3748/wjg.v20.i21.6400 [23] Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth:a meta-analysis[J]. Clin Gastroenterol Hepatol, 2013, 11:483-490. doi: 10.1016/j.cgh.2012.12.011 [24] Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection:Systematic review and meta-analysis[J]. World J Gastroenterol, 2017, 23:6500-6515. doi: 10.3748/wjg.v23.i35.6500 [25] Jackson MA, Goodrich JK, Maxan ME, et al. Original article:Proton pump inhibitors alter the composition of the gut microbiota[J]. Gut, 2016, 65:749-756. doi: 10.1136/gutjnl-2015-310861 [26] Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy[J]. Gut, 2016, 65:870-878. doi: 10.1136/gutjnl-2015-311019 [27] Tahir S, Fallone CA. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment:Bismuth Quadruple Therapy is Almost Always a Reasonable Choice[J]. Can J Gastroenterol Hepatol, 2016, (2):7321574. https://pubmed.ncbi.nlm.nih.gov/26523455/
点击查看大图
计量
- 文章访问数: 263
- HTML全文浏览量: 30
- PDF下载量: 27
- 被引次数: 0